Lead Investigator Evaluates Next-Step for Soliton Pivotal Cellulite Clinical Data
- Preliminary presentation venue, AAD 2020 Annual Meeting, canceled due to coronavirus -
HOUSTON, March 20, 2020 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that Dr. Elizabeth Tanzi, lead investigator on Soliton's pivotal cellulite trial is evaluating alternative presentation opportunities after the American Academy of Dermatology (AAD) canceled its annual meeting due to the current coronavirus (COVID-19) outbreak.
Soliton announced March 3, 2020, the results from its pivotal cellulite trial had been accepted for a podium presentation by Scientific Advisory Board member and leading dermatologist, Dr. Tanzi at the AAD 2020 Annual Meeting. As the medical meeting was cancelled due to COVID-19 concerns, Dr. Tanzi is now exploring alternative presentation options to the scientific community.
"The AAD Annual Meeting is one of the most prestigious dermatology conferences that grants physicians across the globe access to the latest and most innovative technologies in the dermatology industry. We believe that the opportunity to present clinical results at such a venue bestows a specific validation that industry physicians prefer and have come to expect," stated Christopher Capelli, MD, founder, President and CEO of Soliton. "Given the current uncertainty surrounding COVID-19, Dr. Tanzi is evaluating alternative avenues to present our pivotal cellulite results. Once identified, we will immediately communicate that to our shareholders. We appreciate everyone's patience during this challenging time for our country."
Join our more than 200K fans here to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods. Soliton is investigating potential additional capabilities of the RAP technology in clinical and preclinical testing, including the potential to improve the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth and the potential to treat keloid and hypertrophic scars by targeting the stiffened environment in the intracellular matrix.
For more information about the Company, please visit: http://www.soliton.com
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability to announce results from the cellulite pivotal study. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed in our SEC filings, including under the heading "Item 1A. Risk Factors" in the Form 10-K for year ended December 31, 2019 we filed with the SEC and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lead-investigator-evaluates-next-step-for-soliton-pivotal-cellulite-clinical-data-301027230.html
SOURCE Soliton, Inc.
Released March 20, 2020